The trajectory of Sildenafil presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, generating vast sums, the intellectual property end and the subsequent flood of generic alternatives have significantly impacted earnings. This raises questions about the future sustainability of similar drug … Read More